Algorae Pharmaceuticals Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Revenue	-	-	-	0	0.27
Revenue Growth (YoY)	-	-	-	-98.73%	-51.56%
Gross Profit	-	-	-	0	0.27
Selling, General & Admin	0.18	0.2	0.21	-	-
Research & Development	0.85	0.74	1.31	1.46	1.61
Operating Expenses	1.07	1.7	1.52	1.46	1.61
Operating Income	-1.07	-1.7	-1.52	-1.46	-1.34
Interest Expense	-0	-	-	-	-
Interest & Investment Income	0.14	0.13	0.04	-	-
Currency Exchange Gain (Loss)	0.02	-0.02	-0.02	0.01	-0
Other Non Operating Income (Expenses)	-0.63	-0.5	-0.61	-0.91	-0.67
EBT Excluding Unusual Items	-1.54	-2.09	-2.11	-2.36	-2.01
Gain (Loss) on Sale of Investments	-	-	-	-	0.11
Gain (Loss) on Sale of Assets	-	-0	-	-0.01	-
Pretax Income	-1.54	-2.1	-2.11	-2.37	-1.91
Income Tax Expense	-0.74	-	-	-0.41	-0.44
Net Income	-0.8	-2.1	-2.11	-1.96	-1.46
Net Income to Common	-0.8	-2.1	-2.11	-1.96	-1.46
Shares Outstanding (Basic)	1,687	1,663	1,347	876	571
Shares Outstanding (Diluted)	1,687	1,663	1,347	876	571
Shares Change (YoY)	1.46%	23.47%	53.82%	53.24%	-
EPS (Basic)	-0.00	-0.00	-0.00	-0.00	-0.00
EPS (Diluted)	-0.00	-0.00	-0.00	-0.00	-0.00
Free Cash Flow	-0.79	-1.52	-1.99	-2.05	-1.46
Free Cash Flow Per Share	-	-0.00	-0.00	-0.00	-0.00
Gross Margin	-	-	-	100.00%	100.00%
Operating Margin	-	-	-	-42870.16%	-500.05%
Profit Margin	-	-	-	-57483.11%	-544.62%
Free Cash Flow Margin	-	-	-	-60088.31%	-544.97%
EBITDA	-	-1.7	-1.52	-1.46	-1.34
D&A For EBITDA	-	0	0	0	0
EBIT	-1.07	-1.7	-1.52	-1.46	-1.34

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.